Clinical trials
Hepatocellular Carcinoma (HCC) clinical trials
Below are recruiting hepatocellular carcinoma (hcc) clinical trials, each written for real people, not researchers. We’re tracking 484 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07122089RecruitingPhase 2
SIRT plus immunotherapy for liver cancer with portal vein clot
This trial tests a two-step approach for liver cancer that has spread into the portal vein. First, you receive internal radiation (SIRT) to shrink the tumor, followed by immunotherapy drugs (durvalumab with or without tremelimumab) to help your immune system fight the cancer. The goal is to see if this combination is safe and effective.
GrenobleAges 18 years+ - NCT06569498Recruiting
Triple therapy before surgery for liver cancer
This trial tests whether a combination of three drugs given before surgery can help shrink liver cancer and improve outcomes for patients whose tumors can be removed. It is for people with intermediate-stage liver cancer that is still operable.
Fuzhou, FujianAges 18–75 - NCT06523179Recruiting
Liver cancer risk study for people with fatty liver disease
This study looks at your risk of developing liver cancer (hepatocellular carcinoma) if you have a liver condition such as NAFLD or a related disease. It aims to improve how doctors predict who might be at higher risk, so they can offer better monitoring and care.
Milan, MilanoAges 45–75 - NCT05917431RecruitingPhase 2
Radiation plus immunotherapy and targeted pills for liver cancer
This Phase 2 trial studies whether a combination of SBRT (focused radiation) plus tislelizumab and regorafenib can control unresectable or limited-spread liver cancer. It may help by attacking tumors in the liver and immune system to improve shrinkage and control of disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05096715RecruitingPhase 1
Testing atezolizumab plus bevacizumab with SBRT for advanced liver cancer
This Phase 1 trial tests how well a combination treatment works for liver cancer that cannot be removed with surgery or other local treatments. It combines two immune/targeted medicines with a focused type of radiation (SBRT) to control the tumors.
Boston, MassachusettsAges 18 years+ - NCT07018947RecruitingPhase 2
Atezolizumab and bevacizumab before and after surgery for liver cancer
This trial tests whether adding two drugs (atezolizumab and bevacizumab) before and after surgery can lower the chance of liver cancer coming back in people with high-risk HCC. You must be eligible for surgical removal of your tumor.
Badalona, BarcelonaAges 18 years+ - NCT06360042RecruitingPhase 2
Immunotherapy plus anti-angiogenic drugs for advanced liver cancer
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04777942Recruiting
New liver cancer treatment plan for high-risk early-stage patients
This trial studies a treatment approach (a combination given through the liver) for people with early liver cancer that can be surgically removed but has a high chance of coming back. It may help reduce the risk of recurrence after treatment.
Guangzhou, GuangdongAges 18–75 - NCT06561399Recruiting
Triple therapy followed by radiation for liver cancer
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
Fuzhou, FujianAges 18–75 - NCT06577272Recruiting
Predicting cancer return after tumor ablation
This study looks at people with liver cancer who are treated with a procedure called radiofrequency ablation (RFA). It aims to create a tool that can predict the chance of the cancer coming back after treatment.
Hangzhou, ZhejiangAges Any age - NCT06593964Recruiting
TACE with a special gel vs standard beads for liver cancer
This trial compares a new gel-like treatment to standard beads for blocking the blood supply to liver tumors during TACE. It may be an option for patients with certain stages of liver cancer who cannot have surgery or other standard treatments.
NanjingAges 18–80 - NCT07628751Recruiting
Standard care versus radiation therapy for early-stage liver cancer
This study compares two treatment approaches for early-stage liver cancer: standard treatments (like ablation or chemotherapy injected into blood vessels) versus a newer radiation therapy called SABR. The goal is to see which approach works better and is safer for patients with a single small tumor.
WaratahAges 18 years+ - NCT05441475Enrolling by invitationPhase 2
Trial for advanced liver cancer using ABSK-011 plus atezolizumab
This Phase 2 study tests ABSK-011 combined with either atezolizumab or the usual care in people with advanced or unresectable liver cancer. It aims to see if the treatment helps shrink tumors and control the cancer when standard options aren’t working or can’t be used.
Hubei, Shanghai MunicipalityAges 18 years+ - NCT05738616RecruitingPhase 3
Testing lenvatinib plus TACE and immunotherapy before liver surgery
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
Chengdu, SichuanAges 18–75 - NCT04348838Recruiting
Study of people newly diagnosed with liver cancer in France
This study follows people with hepatocellular carcinoma (HCC), a type of liver cancer, to learn how it changes over time. It may help improve understanding of which patients benefit from different care approaches.
AmiensAges 18 years+ - NCT05620771RecruitingPhase 2
Y-90 radioembolization plus treatment for high-risk liver cancer
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
Chicago, IllinoisAges 18 years+ - NCT05862337RecruitingPhase 3
New immune plus anti-cancer pills to prevent liver cancer returning
This Phase 3 trial studies anlotinib capsules plus penpulimab (an immune therapy) to help prevent hepatocellular carcinoma from coming back after it has been fully removed or fully destroyed. It may help high-risk patients lower the chance of recurrence and improve survival.
Bengbu, AnhuiAges 18–75 - NCT06218420RecruitingPhase 2
Radiation to bridge to liver transplant
This study tests whether a precise type of radiation (called stereotactic body radiotherapy or SBRT) can be used as a 'bridge' to keep your liver cancer from growing while you wait for a liver transplant. It may help more people stay healthy enough to receive a transplant.
ParisAges 18 years+ - NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+ - NCT06374485RecruitingPhase 1
AU409 capsule for advanced liver cancer after other treatments fail
This trial tests a new capsule called AU409 for people with advanced liver cancer (HCC) who have already tried standard treatments and they no longer work. The goal is to see if AU409 can help control the cancer.
Hong KongAges 18–75 - NCT05920863RecruitingPhase 2
Lenvatinib, immunotherapy, plus liver artery treatment before surgery
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
Hangzhou, ZhejiangAges 18–75 - NCT06280105RecruitingPhase 2
Testing cadonilimab and regorafenib for liver cancer after other treatments fail
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
Fuzhou, FujianAges 18–75 - NCT06382103Recruiting
Liver cancer study after surgery or pre-surgery therapy
This study looks at genetic markers in the blood of people with liver cancer who are having surgery, either right away or after some treatment first. It aims to find out why some patients do better, which could help personalize care.
ShanghaiAges Any age - NCT06498622RecruitingPhase 2
Liver cancer relapse prevention after surgery
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
Fuyang, AnhuiAges 18–80
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma (hcc)?
- Yes. Clin2 currently lists 484 recruiting hepatocellular carcinoma (hcc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma (hcc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma (hcc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.